Iressa Cross-Over Study Could Show Clinical Benefit, AZ Says; ODAC Is Wary

AstraZeneca believes a controlled, cross-over trial could be used to confirm the sympom benefit of Iressa in refractory non-small cell lung cancer patients, VP-Medical Director of Oncology George Blackledge, MD, said during FDA's Oncologic Drugs Advisory Committee Sept. 24

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet